The long-term use of muscle relaxants may benefit patients with painful spasms or cramps and neck pain, according to a systematic review of clinical studies.
FDA has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD).
The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.
A recent review highlighted existing literature on the gut microbiome and type 2 diabetes and explored how focusing on the gut microbiome could assist with diabetes management.
Researchers found that brief bouts of anger can impair the ability of blood vessels to expand and contract, which might have consequences for heart health.